Ganaxolone for seizures in young children with CDKL5 deficiency
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new medicine, ganaxolone, to see if it can reduce seizures in babies and toddlers with CDKL5 deficiency disorder. It aims to help children whose seizures are not controlled by current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and 2 years old.
- Your child must have a confirmed CDKL5 gene change that causes the condition.
- Your child has had at least 8 countable seizures in the past 28 days.
- Your child has tried at least one anti-seizure medicine that didn't work well enough.
- Your child's seizure medicines must be stable for at least 2 weeks before the study starts.
- You must be able to keep a daily seizure diary and give the study medicine with food three times a day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking daily warm baths at home can safely reduce seizures in children with CDKL5 deficiency disorder. It may help families looking for a non-medication way to manage seizures.
This study tests whether a medicine called ganaxolone can reduce irritability (frequent tantrums or aggression) in children with autism. The child will take the drug or a placebo (a dummy pill) for a period, and researchers will monitor behavior and brain activity.
This trial tests an oral cannabidiol medicine (Epidiolex) for children whose seizures are not controlled by other treatments. It aims to see if adding this drug can reduce seizure frequency.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This study looks at what happens when children with Dravet or Lennox Gastaut syndrome switch from a homemade or artisanal CBD product to Epidiolex, a prescription CBD. The goal is to see if the switch is safe and helps control seizures.
Hear when a new CDKL5 Deficiency Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.